These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38782549)

  • 1. Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years.
    Burmester GR; Gottenberg JE; Caporali R; Winthrop KL; Tanaka Y; Ekoka Omoruyi EV; Rajendran V; Van Hoek P; Van Beneden K; Takeuchi T; Westhovens R; Aletaha D
    Ann Rheum Dis; 2024 Aug; 83(9):1110-1117. PubMed ID: 38782549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years.
    Winthrop KL; Tanaka Y; Takeuchi T; Kivitz A; Matzkies F; Genovese MC; Jiang D; Chen K; Bartok B; Jahreis A; Besuyen R; Burmester GR; Gottenberg JE
    Ann Rheum Dis; 2022 Feb; 81(2):184-192. PubMed ID: 34740884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years.
    Ishiguro N; Tanaka Y; Matsubara T; Atsumi T; Amano K; Sugiyama E; Yamaoka K; Winthrop K; Kivitz A; Burmester GR; Gottenberg JE; Genovese MC; Matzkies F; Guo Y; Jiang D; Bartok B; Pechonkina A; Kondo A; Besuyen R; Takeuchi T
    Mod Rheumatol; 2023 Jan; 33(1):64-72. PubMed ID: 35365828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
    Taylor PC; Takeuchi T; Burmester GR; Durez P; Smolen JS; Deberdt W; Issa M; Terres JR; Bello N; Winthrop KL
    Ann Rheum Dis; 2022 Mar; 81(3):335-343. PubMed ID: 34706874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
    Genovese MC; Kalunian K; Gottenberg JE; Mozaffarian N; Bartok B; Matzkies F; Gao J; Guo Y; Tasset C; Sundy JS; de Vlam K; Walker D; Takeuchi T
    JAMA; 2019 Jul; 322(4):315-325. PubMed ID: 31334793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis.
    Combe B; Besuyen R; Gómez-Centeno A; Matsubara T; Sancho Jimenez JJ; Yin Z; Buch MH
    Rheumatol Ther; 2023 Feb; 10(1):35-51. PubMed ID: 36205910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.
    Mease P; Coates LC; Helliwell PS; Stanislavchuk M; Rychlewska-Hanczewska A; Dudek A; Abi-Saab W; Tasset C; Meuleners L; Harrison P; Besuyen R; Van der Aa A; Mozaffarian N; Greer JM; Kunder R; Van den Bosch F; Gladman DD
    Lancet; 2018 Dec; 392(10162):2367-2377. PubMed ID: 30360969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis.
    Balsa A; Wassenberg S; Tanaka Y; Tournadre A; Orzechowski HD; Rajendran V; Lendl U; Stiers PJ; Watson C; Caporali R; Galloway J; Verschueren P
    Rheumatol Ther; 2023 Dec; 10(6):1555-1574. PubMed ID: 37747626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
    Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
    Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exposure-response relationships for the efficacy and safety of filgotinib and its metabolite GS-829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies.
    Meng A; Anderson K; Nelson C; Ni L; Chuang SM; Bellanti F; Chang P; Comisar C; Kearney BP; Bartok B; Mathias A
    Br J Clin Pharmacol; 2022 Jul; 88(7):3211-3221. PubMed ID: 35072287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme.
    Fleischmann R; Curtis JR; Charles-Schoeman C; Mysler E; Yamaoka K; Richez C; Palac H; Dilley D; Liu J; Strengholt S; Burmester G
    Ann Rheum Dis; 2023 Sep; 82(9):1130-1141. PubMed ID: 37308218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure.
    Simpson EL; Silverberg JI; Nosbaum A; Winthrop K; Guttman-Yassky E; Hoffmeister KM; Egeberg A; Valdez H; Fan H; Farooqui SA; Chan G; Alderfer J; Romero W; Chittuluru K
    Am J Clin Dermatol; 2024 Jul; 25(4):639-654. PubMed ID: 38888681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
    Westhovens R; Taylor PC; Alten R; Pavlova D; Enríquez-Sosa F; Mazur M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P
    Ann Rheum Dis; 2017 Jun; 76(6):998-1008. PubMed ID: 27993829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
    van der Heijde D; Baraliakos X; Gensler LS; Maksymowych WP; Tseluyko V; Nadashkevich O; Abi-Saab W; Tasset C; Meuleners L; Besuyen R; Hendrikx T; Mozaffarian N; Liu K; Greer JM; Deodhar A; Landewé R
    Lancet; 2018 Dec; 392(10162):2378-2387. PubMed ID: 30360970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of filgotinib in rheumatoid arthritis patients: data from the GISEA registry.
    Fornaro M; Caporali R; Biggioggero M; Bugatti S; De Stefano L; Cauli A; Congia M; Conti F; Chimenti MS; Bazzani C; Perniola S; Atzeni F; Lapadula G; Ferraccioli G; Iannone F;
    Clin Exp Rheumatol; 2024 May; 42(5):1043-1050. PubMed ID: 38634362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).
    Kavanaugh A; Kremer J; Ponce L; Cseuz R; Reshetko OV; Stanislavchuk M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P
    Ann Rheum Dis; 2017 Jun; 76(6):1009-1019. PubMed ID: 27993828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs.
    Kavanaugh A; Westhovens RR; Winthrop KL; Lee SJ; Tan Y; An D; Ye L; Sundy JS; Besuyen R; Meuleners L; Stanislavchuk M; Spindler AJ; Greenwald M; Alten R; Genovese MC
    J Rheumatol; 2021 Aug; 48(8):1230-1238. PubMed ID: 33526618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cumulative incidence and risk of infection in patients with rheumatoid arthritis treated with janus kinase inhibitors: A systematic review and meta-analysis.
    Ouranos K; Avila DV; Mylona EK; Vassilopoulos A; Vassilopoulos S; Shehadeh F; Mylonakis E
    PLoS One; 2024; 19(7):e0306548. PubMed ID: 39083492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.
    Takeuchi T; Tanaka Y; Tanaka S; Kawakami A; Song YW; Chen YH; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Nakashima Y; Shiomi T; Yamada E
    Arthritis Res Ther; 2020 Mar; 22(1):47. PubMed ID: 32164762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
    Ytterberg SR; Bhatt DL; Mikuls TR; Koch GG; Fleischmann R; Rivas JL; Germino R; Menon S; Sun Y; Wang C; Shapiro AB; Kanik KS; Connell CA;
    N Engl J Med; 2022 Jan; 386(4):316-326. PubMed ID: 35081280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.